scholarly journals Brain proteome changes in female Brd1 mice unmask dendritic spine pathology and show enrichment for schizophrenia risk

2019 ◽  
Vol 124 ◽  
pp. 479-488 ◽  
Author(s):  
Veerle Paternoster ◽  
Maria Svanborg ◽  
Anders Valdemar Edhager ◽  
Anto P. Rajkumar ◽  
Esben Ahlburg Eickhardt ◽  
...  
2020 ◽  
Vol 17 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Jing Ma ◽  
Yuan Gao ◽  
Wei Tang ◽  
Wei Huang ◽  
Yong Tang

Background: Studies have suggested that cognitive impairment in Alzheimer’s disease (AD) is associated with dendritic spine loss, especially in the hippocampus. Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus. However, little is known about whether FLX affects the pathogenesis of AD in the middle-tolate stage and whether its effects are correlated with the amelioration of hippocampal dendritic dysfunction. Previously, it has been observed that FLX improves the spatial learning ability of middleaged APP/PS1 mice. Objective: In the present study, we further characterized the impact of FLX on dendritic spines in the hippocampus of middle-aged APP/PS1 mice. Results: It has been found that the numbers of dendritic spines in dentate gyrus (DG), CA1 and CA2/3 of hippocampus were significantly increased by FLX. Meanwhile, FLX effectively attenuated hyperphosphorylation of tau at Ser396 and elevated protein levels of postsynaptic density 95 (PSD-95) and synapsin-1 (SYN-1) in the hippocampus. Conclusion: These results indicated that the enhanced learning ability observed in FLX-treated middle-aged APP/PS1 mice might be associated with remarkable mitigation of hippocampal dendritic spine pathology by FLX and suggested that FLX might be explored as a new strategy for therapy of AD in the middle-to-late stage.


Neuroscience ◽  
2019 ◽  
Vol 396 ◽  
pp. 36-45 ◽  
Author(s):  
Hiram Tendilla-Beltrán ◽  
Rubén Antonio Vázquez-Roque ◽  
Andrea Judith Vázquez-Hernández ◽  
Linda Garcés-Ramírez ◽  
Gonzalo Flores

2014 ◽  
Vol 13 (8) ◽  
pp. 3763-3770 ◽  
Author(s):  
Yaoyang Zhang ◽  
Bing Shan ◽  
Monica Boyle ◽  
Jacqueline Liu ◽  
Lujian Liao ◽  
...  

PEDIATRICS ◽  
1999 ◽  
Vol 104 (2) ◽  
pp. e21-e21 ◽  
Author(s):  
Luis Benı́tez-Bribiesca ◽  
Irma De la Rosa-Alvarez ◽  
Armando Mansilla-Olivares

2014 ◽  
Vol 71 (12) ◽  
pp. 1323 ◽  
Author(s):  
Glenn T. Konopaske ◽  
Nicholas Lange ◽  
Joseph T. Coyle ◽  
Francine M. Benes

eLife ◽  
2019 ◽  
Vol 8 ◽  
Author(s):  
Oleksandr Yagensky ◽  
Mahdokht Kohansal-Nodehi ◽  
Saravanan Gunaseelan ◽  
Tamara Rabe ◽  
Saima Zafar ◽  
...  

Alzheimer’s disease is the most prevalent neurodegenerative disorder leading to progressive cognitive decline. Despite decades of research, understanding AD progression at the molecular level, especially at its early stages, remains elusive. Here, we identified several presymptomatic AD markers by investigating brain proteome changes over the course of neurodegeneration in a transgenic mouse model of AD (3×Tg-AD). We show that one of these markers, heme-binding protein 1 (Hebp1), is elevated in the brains of both 3×Tg-AD mice and patients affected by rapidly-progressing forms of AD. Hebp1, predominantly expressed in neurons, interacts with the mitochondrial contact site complex (MICOS) and exhibits a perimitochondrial localization. Strikingly, wildtype, but not Hebp1-deficient, neurons showed elevated cytotoxicity in response to heme-induced apoptosis. Increased survivability in Hebp1-deficient neurons is conferred by blocking the activation of the mitochondrial-associated caspase signaling pathway. Taken together, our data highlight a role of Hebp1 in progressive neuronal loss during AD progression.


2004 ◽  
Vol 35 (01) ◽  
Author(s):  
AM Kaindl ◽  
D Sagi ◽  
U Felderhoff-Mueser ◽  
M Sifringer ◽  
P Bittigau ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Abhisarika Patnaik ◽  
Marta Zagrebelsky ◽  
Martin Korte ◽  
Andreas Holz

2017 ◽  
Vol 9 (5) ◽  
pp. 716-731 ◽  
Author(s):  
Sonja Blumenstock ◽  
Eva F Rodrigues ◽  
Finn Peters ◽  
Lidia Blazquez‐Llorca ◽  
Felix Schmidt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document